Cost-effective reimbursement analysis for medical technologies in Europe
Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries
Recent news and posts
A new task group for multi-cancer detection tests at the UK National Screening Committee
On July 12, 2024, the UK National Screening Committee (UK NSC) announced it would appoint a new task group for multi-cancer detection (MCD) tests.
The UK NSC previously assessed MCD for potential inclusion into screening programs. However, no recommendations were made regarding the use of MCDs for screening in the UK. There was no evidence that their use in a screening program prevents deaths from cancer or improves quality of life. Despite this, MCDs are a potentially transformative type of technology. A wide range of MCDs are currently under development. The UK NSC conducts horizon-scanning activities and regularly engages with relevant groups, including test developers, research funders, and the NHS.
The new MCD task group will bring together researchers, clinical experts, public health experts, and patient and public representatives. The following was commissioned to the MCD group:
- To review different methods for the evaluation of MCDs, from which UK NSC will derive a position statement;
- Support the UK NSC and its sub-committees to understand and address any ethical implications of these tests;
- Support UK NSC in developing a roadmap that integrates the different aspects into a possible MCD screening program structure.
See the full details here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.